Hôpital Necker-Enfants Malades
Paris, 75015, France
NCT Number: NCT04581460
The management of patients with primary immune deficiency is increasingly codified, however contraception and pregnancy have not yet extensively studied or codified, and the medical monitoring and the prevention of infectious complications thus remains at the discretion of the practitioner.
The aim the research is to study the obstetric features and outcome of patients with primary immune defects.
Looking for future studies?
Notify Me18 year and older
Female
Observational
Paris, 75015, France
Primary immune deficiencies constitute a large group of immune system disorders of genetic origin which can associate, to varying degrees, an increased susceptibility to infections and immunopathological manifestations: allergy, inflammation, autoimmunity, lymphoproliferation, tumors malignant.
Although their prevalence remains underestimated, there has been an increase in the number of cases diagnosed in the past 10 years. The national average prevalence is 8.6 patients per 100,000 inhabitants and the diagnostic incidence is 400 new cases per year in France. Major improvement in the management of primary immunodeficiencies have drastically changed patients outcome. Most patients now reach adulthood and the possibility of carrying out a pregnancy project, that has already reported for patients suffering from hypogammaglobulinemia or variable common immune deficiency, is now increasingly reported for other types of inherited immunodeficiencies. Whereas the management of patients with hereditary immunodeficiencies is increasingly codified, contraception and pregnancy have not yet been the subject of recommendations: medical monitoring and the prevention of infectious complications thus remain at the discretion of the practitioner.
The aim the research is to study the obstetric experiences of patients with a primary immune deficiency, paying particular attention to infectious complications.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Questionnaire intended for patients on the course of pregnancy and postpartum, the neonatal period and contraceptive modalities.
Time frame: 18 months
Number of infectious events at any time during pregnancy and post-partum
Time frame: Up to 50 years
Number of infectious gynecological complications during contraception
Time frame: Up to 50 years
Number of pregnancies during reproductive age period
Time frame: Up to 9 months
Rate of early or late miscarriage, completed pregnancy, live birth and childbearing
Time frame: 9 months
Number of treatments aiming at preventing infections
Time frame: 9 months
Presence/absence of screening for infections
Time frame: 9 months
Rate of obstetric complications
Time frame: Up to 50 years
Number of unwanted pregnancies
Time frame: Up to 50 years
Number of non-infectious complications of contraception
Time frame: 3 months
Number of complications during neonatal period, including death
Assistance Publique - Hôpitaux de Paris
Other
Acronym: PREPI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04919018
Abnormalities, Multiple, Bronchial Diseases
St Louis, Missouri, United States
View Trial DetailsNCT04702243
Abnormalities, Multiple, Bronchial Diseases
Palo Alto, California, United States
View Trial DetailsNCT06014463
Behavior, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Ankara, Hacettepe Unıversity, Turkey (Türkiye)
View Trial DetailsNCT02711228
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Montreal, Canada
View Trial Details